Metacrine Updates MET642 Clinical Development Milestone and Reports Second-Quarter 2021 Results
August 12, 2021 08:05 ET
|
Metacrine, Inc.
Interim data from the Phase 2a trial of MET642 in patients with NASH now expected early in the fourth quarter of 2021Topline results from a Phase 2a trial of MET409 in combination with empagliflozin...
Metacrine to Present at 2021 Canaccord Genuity Growth Conference
August 09, 2021 08:05 ET
|
Metacrine, Inc.
SAN DIEGO, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and...
Metacrine and Its Partners to Present Data at the EASL International Liver Congress™ 2021
June 17, 2021 08:05 ET
|
Metacrine, Inc.
SAN DIEGO, June 17, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and...
Metacrine Achieves Full Enrollment for MET409 Phase 2a Combination Trial in Patients With Type 2 Diabetes and NASH
June 02, 2021 08:05 ET
|
Metacrine, Inc.
Topline data expected to be reported in the fourth quarter of 2021 SAN DIEGO, June 02, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering...
Metacrine to Present at 2021 Jefferies Healthcare Conference
May 26, 2021 08:05 ET
|
Metacrine, Inc.
SAN DIEGO, May 26, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal...
Metacrine Achieves Enrollment Target for MET642 Phase 2a Trial Interim Analysis
May 18, 2021 08:05 ET
|
Metacrine, Inc.
Interim data from the first 60 patients with NASH on track to be reported in the fourth quarter of 2021Enrollment continuing for up to 180 patients, with full topline results expected to be reported...
Metacrine Appoints Dr. Julia C. Owens to Its Board of Directors
April 05, 2021 16:05 ET
|
Metacrine, Inc.
SAN DIEGO, April 05, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and...
Global Non-alcoholic Steatohepatitis Biomarkers Market Accounted for US$ 556.6 Billion in 2019 and is Estimated to be US$ 8177.9 Billion by 2029 and is Anticipated to Register a CAGR of 31.3%
August 18, 2020 10:05 ET
|
PMI
Covina, CA, Aug. 18, 2020 (GLOBE NEWSWIRE) -- The report "Global Non-alcoholic Steatohepatitis Biomarkers Market, By Type (Serum Biomarkers, Hepatic Fibrosis Biomarkers, Apoptosis Biomarkers,...
Endonovo Therapeutics Files 8K With SEC Regarding SofPulse®
March 02, 2020 07:30 ET
|
Endonovo Therapeutics, Inc.
Los Angeles, CA, March 02, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company") today announced it has filed an 8K with the Securities and Exchange...
Metacrine to Present at Jefferies 2019 London Healthcare Conference
November 18, 2019 07:30 ET
|
Metacrine, Inc.
SAN DIEGO, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Metacrine, Inc., a clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat liver and...